PRILOCAINE HCL 4% EPINEPH 1:200000INJ 40 MG
PRILOCAINE HYDROCHLORIDE : 40 MG EPINEPHRINE : 0.005 MG · DIN 00393746 · NOVOCOL PHARMACEUTICAL OF CANADA INC
Health Canada status: MARKETED
What is PRILOCAINE HCL 4% EPINEPH 1:200000INJ?
PRILOCAINE HCL 4% EPINEPH 1:200000INJ 40 MG contains PRILOCAINE HYDROCHLORIDE : 40 MG EPINEPHRINE : 0.005 MG. It is listed in the Health Canada Drug Product Database under DIN 00393746, held by NOVOCOL PHARMACEUTICAL OF CANADA INC, supplied as SOLUTION for BLOCK/INFILTRATION administration. Health Canada currently lists it as marketed, status dated 31-Dec-1977. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 00393746 |
|---|---|
| Brand name | PRILOCAINE HCL 4% EPINEPH 1:200000INJ |
| Generic / active ingredient | PRILOCAINE HYDROCHLORIDE : 40 MG EPINEPHRINE : 0.005 MG |
| Manufacturer | NOVOCOL PHARMACEUTICAL OF CANADA INC |
| Strength | 40 MG |
| Dosage form | SOLUTION |
| Route of administration | BLOCK/INFILTRATION |
| Schedule | Ethical |
| ATC code | N01BB54 PRILOCAINE, COMBINATIONS |
| AHFS class | 72:00.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 31-Dec-1977 |
| Original market date | 1977-12-31 00:00:00 |
What can be used instead?
Other Canadian products sharing ATC code N01BB54 PRILOCAINE, COMBINATIONS. 4 of 5 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| 4% CITANEST FORTE DENTAL WITH EPINEPHRINE 1:200,000 | 0.005 MG | SOLUTION | DENTSPLY CANADA LIMITED | MARKETED | DIN 02347695 |
| EMLA CREAM | 2.5 % | CREAM | ASPEN PHARMACARE CANADA INC. | MARKETED | DIN 00886858 |
| EMLA PATCH | 2.5 % | PATCH | ASPEN PHARMACARE CANADA INC. | MARKETED | DIN 02057794 |
| DENTSPLY 4% PRILOCAINE AND EPINEPHRINE INJECTION 1:200,000 | 5 MCG | SOLUTION | DENTSPLY CANADA LIMITED | CANCELLED POST MARKET | DIN 00519227 |
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.